Patent 7090874 was granted and assigned to Kaneka Corporation on August, 2006 by the United States Patent and Trademark Office.
The object of the present invention is to provide PPARγ ligand derived from naturally occurring sources and a composition for preventing and/or improving Insulin Resistance Syndrome, diabetes mellitus, obesity or visceral fat obesity comprising the PPARγ ligand as an active agent.